NASDAQ:CELC

Celcuity (CELC) Stock Forecast, Price & News

$9.80

+0.23 (+2.40%)

(As of 11:28 AM ET)

Compare

Today's Range: $9.51
▼
$10.14
50-Day Range: $8.96
▼
$10.75
52-Week Range: $7.50
▼
$14.40

Volume: 6,042 shs
Average Volume: 76,624 shs
Market Capitalization: $216.48 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $25.00

Celcuity MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 161.2% Upside
$25.00 Price Target
Short Interest: Bearish
26.07% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.30
Based on 2 Articles This Week
Insider Trading: Selling Shares
$6,194 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($2.77) to ($2.48) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.97 out of 5 stars

Medical Sector

608th out of 961 stocks

Medical Laboratories Industry

15th out of 23 stocks

3.5

Analyst's Opinion

Consensus Rating
Celcuity has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $25.00, Celcuity has a forecasted upside of 161.2% from its current price of $9.57.
Amount of Analyst Coverage
Celcuity has only been the subject of 1 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
26.07% of the float of Celcuity has been sold short.
Short Interest Ratio / Days to Cover
Celcuity has a short interest ratio ("days to cover") of 29.1, which indicates bearish sentiment.
Change versus previous month
Short interest in Celcuity has recently increased by 2.55%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Celcuity does not currently pay a dividend.
Dividend Growth
Celcuity does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CELC.

1.8

News and Social Media Coverage

News Sentiment
Celcuity has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Celcuity this week, compared to 1 article on an average week.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Celcuity insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,194.00 in company stock.
Percentage Held by Insiders
24.29% of the stock of Celcuity is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
63.33% of the stock of Celcuity is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Celcuity are expected to grow in the coming year, from ($2.77) to ($2.48) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Celcuity is -3.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Celcuity is -3.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Celcuity has a P/B Ratio of 1.55. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Celcuity (NASDAQ:CELC) Stock

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

CELC Price History

30 days | 90 days | 365 days | Advanced Chart

CELC Stock News Headlines

September 24, 2023 | americanbankingnews.com

Celcuity (NASDAQ:CELC) Stock Rating Reaffirmed by Needham & Company LLC

September 14, 2023 | markets.businessinsider.com

Will Celcuity's VIKTORIA-1 Hit The Target?

September 26, 2023 | Chaikin Analytics (Ad)

His system isolated NVIDIA - Here's His Next Buy.

Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.

September 7, 2023 | finance.yahoo.com

Celcuity to Host Virtual Science Day for Investors

August 23, 2023 | finanznachrichten.de

Celcuity Inc.: Celcuity Enters into a Clinical Trial Collaboration and Supply Agreement with

August 23, 2023 | markets.businessinsider.com

Celcuity (CELC) Has a New Rating from Craig-Hallum

August 22, 2023 | finance.yahoo.com

Celcuity Announces Plan to Conduct Phase 1b/2 Clinical Trial in Metastatic Castration Resistant Prostate Cancer

August 22, 2023 | finance.yahoo.com

Celcuity Enters into a Clinical Trial Collaboration and Supply Agreement with Bayer to Provide Nubeqa® (darolutamide) for Planned Phase 1b/2 Clinical Trial

September 26, 2023 | Chaikin Analytics (Ad)

His system isolated NVIDIA - Here's His Next Buy.

Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.

August 11, 2023 | finance.yahoo.com

Q2 2023 Celcuity Inc Earnings Call

August 10, 2023 | msn.com

BRCC GAAP EPS of -$0.07 in-line, revenue of $91.9M beats by $1.15M

August 10, 2023 | finance.yahoo.com

Celcuity Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Updates

August 3, 2023 | finance.yahoo.com

Celcuity Inc. Schedules Release of Second Quarter 2023 Financial Results and Webcast/Conference Call

July 31, 2023 | finance.yahoo.com

Celcuity to Participate in the BTIG Virtual Biotechnology Conference 2023

July 27, 2023 | finance.yahoo.com

Celcuity Inc. (NASDAQ:CELC) stock most popular amongst individual investors who own 23%, while private equity firms hold 22%

June 20, 2023 | finanznachrichten.de

Celcuity Inc.: Celcuity Set to Join Russell 2000 and 3000 Indexes

June 20, 2023 | finance.yahoo.com

Celcuity Set to Join Russell 2000 and 3000 Indexes

May 24, 2023 | finance.yahoo.com

Insiders of Celcuity Getting Good Value On Their US$1.6m Investment

May 16, 2023 | msn.com

Needham Reiterates Celcuity (CELC) Buy Recommendation

May 16, 2023 | finance.yahoo.com

Q1 2023 Celcuity Inc Earnings Call

May 15, 2023 | finance.yahoo.com

Celcuity Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Updates

May 15, 2023 | markets.businessinsider.com

Craig-Hallum Keeps Their Buy Rating on Celcuity (CELC)

May 13, 2023 | marketwatch.com

Celcuity Presents Updated Results from Phase 1b Study of Gedatolisib in Treatment-Naive Patients at the 2023 ESMO Breast Cancer Annual Congress

May 12, 2023 | msn.com

A Preview Of Celcuity's Earnings

May 12, 2023 | msn.com

Celcuity gedatolisib combo shows promise in phase 1b trial in breast cancer patients

May 8, 2023 | finance.yahoo.com

Celcuity Inc. Schedules Release of First Quarter 2023 Financial Results and Webcast/Conference Call

May 8, 2023 | finance.yahoo.com

Celcuity to Present Updated Results for Treatment-Naïve Patients from Phase 1b Study of Gedatolisib at the 2023 ESMO Breast Cancer Annual Congress

See More Headlines

Receive CELC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Celcuity and its competitors with MarketBeat's FREE daily newsletter.

CELC Company Calendar

Last Earnings: 8/10/2023
Today: 9/26/2023
Next Earnings (Estimated): 11/09/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Medical laboratories
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CELC
CUSIP: N/A
CIK: 1603454
Web: www.celcuity.com
Phone: (763) 392-0767
Fax: N/A
Employees: 45
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $25.00
High Stock Price Forecast: $25.00
Low Stock Price Forecast: $25.00
Forecasted Upside/Downside: +161.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.65)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-40,370,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -47.73%
Return on Assets: -35.04%

Debt

Debt-to-Equity Ratio: 0.33
Current Ratio: 21.58
Quick Ratio: 21.58

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.17 per share
Price / Book: 1.55

Miscellaneous

Outstanding Shares: 22,090,000
Free Float: 16,724,000
Market Cap: $211.40 million
Optionable: Not Optionable
Beta: 0.60

The Best High-Yield Dividend Stocks for 2023

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Mr. Brian F. Sullivan (Age 61)
Co-Founder, Chairman & CEO
Comp: $105.77k

Dr. Lance G. Laing Ph.D. (Age 61)
Co-Founder, Chief Science Officer, VP, Sec. & Director
Comp: $325.38k

Ms. Vicky Hahne (Age 57)
Chief Financial Officer
Comp: $210k

Dr. John R. MacDonald Dabt (Age 68)
Ph., Ph.D., Sr. VP of R&D

Ms. Sheri Smith
Acting Head of Clinical Operations

Mr. Igor Gorbatchevsky M.D.
Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CELC Stock - Frequently Asked Questions

Should I buy or sell Celcuity stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celcuity in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CELC shares.
View CELC analyst ratings or view top-rated stocks.
What is Celcuity's stock price forecast for 2023?: 1 equities research analysts have issued 1 year target prices for Celcuity's stock. Their CELC share price forecasts range from $25.00 to $25.00. On average, they anticipate the company's share price to reach $25.00 in the next year. This suggests a possible upside of 161.2% from the stock's current price.
View analysts price targets for CELC or view top-rated stocks among Wall Street analysts.
How have CELC shares performed in 2023?: Celcuity's stock was trading at $14.01 on January 1st, 2023. Since then, CELC shares have decreased by 31.7% and is now trading at $9.57.
View the best growth stocks for 2023 here.
When is Celcuity's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our CELC earnings forecast.
How were Celcuity's earnings last quarter?: Celcuity Inc. (NASDAQ:CELC) released its quarterly earnings results on Thursday, August, 10th. The company reported ($0.66) EPS for the quarter, beating the consensus estimate of ($0.67) by $0.01.
What other stocks do shareholders of Celcuity own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Celcuity investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), Evoke Pharma (EVOK), Amicus Therapeutics (FOLD), Allena Pharmaceuticals (ALNA), Genocea Biosciences (GNCA), Idera Pharmaceuticals (IDRA) and Ovid Therapeutics (OVID).

When did Celcuity IPO?: (CELC) raised $18 million in an initial public offering on Wednesday, September 20th 2017. The company issued 2,000,000 shares at a price of $8.00-$10.00 per share. Craig-Hallum Capital Group served as the underwriter for the IPO.
What is Celcuity's stock symbol?: Celcuity trades on the NASDAQ under the ticker symbol "CELC."
Who are Celcuity's major shareholders?: Celcuity's stock is owned by a number of retail and institutional investors. Top institutional investors include Commodore Capital LP (6.66%), BlackRock Inc. (4.21%), Captrust Financial Advisors (2.57%), Geode Capital Management LLC (1.36%), State Street Corp (1.21%) and Northern Trust Corp (0.84%). Insiders that own company stock include Brian F Sullivan, Richard E Buller and Richard Nigon.
View institutional ownership trends.
How do I buy shares of Celcuity?: Shares of CELC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Celcuity's stock price today?: One share of CELC stock can currently be purchased for approximately $9.57.
How much money does Celcuity make?: Celcuity (NASDAQ:CELC) has a market capitalization of $211.40 million. The company earns $-40,370,000.00 in net income (profit) each year or ($2.65) on an earnings per share basis.
How can I contact Celcuity?: Celcuity's mailing address is 16305 36TH AVENUE NORTH SUITE 100, MINNEAPOLIS MN, 55446. The official website for the company is www.celcuity.com. The company can be reached via phone at (763) 392-0767.

This page (NASDAQ:CELC) was last updated on 9/26/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial